Lessons From An HCV Vaccine Trial
Andrea L. Cox, MD, PhD, discusses the implications of discovering that an experimental vaccine was not effective at preventing chronic hepatitis C virus.
Watch
Finding Resources For Antiretroviral Stewardship
Daniel Chastain, PharmD, BCIDP, discusses how antiretroviral stewardship might practically be implemented in the context that antimicrobial stewardship as a whole is often underdeveloped.
Challenges Developing a Hepatitis C Vaccine
Andrea L. Cox, MD, PhD, discusses some of the challenges in developing a vaccine for hepatitis C and details the results of a vaccine trial.
Confidential Community Care For HIV
Max Brito, MD, MPH, explains the value of bringing safe, confidential, and non-stigmatizing HIV treatment to the community at IDWeek2019.
What is Antiretroviral Stewardship?
Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship.
Hepatitis C and the Opioid Epidemic
Andrea L. Cox, MD, PhD, compares the rates of hepatitis C and hepatitis B diagnoses since the start of the opioid epidemic.
Why Everyone Needs a Flu Shot
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, explains why everyone needs a flu shot and addresses skepticism toward the vaccine.
Are Massive Global Pandemics Still Possible?
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses changes in public health and society since the early 20th century in response to speculation about whether large-scale global pandemics are still possible in the 21st century.
Benefits of Connecting HIV Care to Incarcerated People
Pamela Gorman, RN, ACRN, describes the benefits of connecting care to incarcerated people with HIV.
Transitional Care Coordination For Incarcerated People With HIV
Pamela Gorman, RN, ACRN, describes a transitional care coordination program for incarcerated individuals with HIV returning to the community primary care setting.
The State of Antimicrobial Stewardship
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, describes the current state of antimicrobial stewardship efforts.
Making HIV Treatment and Prevention Relevant to Black Women
Rasheeta Chandler, PhD, RN, APRN-BC, FNP-BC, FAANP, FAAN, explains the need to incorporate women at-risk for or living with HIV into the decision-making process if we are to end the epidemic.
Are Transgender Women Underrepresented in Sexual Health Research?
Max Brito, MD, MPH, remarks on the underrepresentation of transgender women in HIV and other sexual health research.
Why #IDTwitter?
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses his journey from social media skeptic to “Twitter convert.”
ID Themes of 2019
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses some of the broader themes in ID over the course of 2019.
Noteworthy ID Papers of 2019
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses noteworthy infectious disease papers published in 2019.
High Rate of Errors in HIV Therapies
Daniel B. Chastain, PharmD, BCIDP, AAHIVP, discusses a retrospective study of errors occurring in the treatment of patients with HIV.
HIV Care as Patient and Provider
Jason Tokumoto, MD, discusses how occupying the role of both patient and physician can provide a human perspective on HIV care.
Developing Options For Congenital CMV
Brenna Hughes, MD, MSc, explains why we need more effective options for congenital CMV.
The Role of Guidelines in ID Treatment
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, weighs in on the role of guidelines in ID treatment.
EHR, Outreach, and Community Partners
Pamela Gorman, RN, ACRN, discusses the importance of clinics having team members who come from the community patients are being recruited from.
The Impact of Discovering U=U
Jason Tokumoto, MD, discusses recent developments in HIV treatment and prevention, focusing on the impact of “U=U.”
Expectations For Upcoming Long-Acting ART
Jason Schafer, PharmD, MPH, BCPS AQ-ID, discusses upcoming long-acting therapies for HIV.
What to Expect in December's Editor-in-Chief Letter
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.
Does CMV-HIG Have an Effect on Congenital Infections?
Brenna Hughes, MD, MSc, discusses the hypothesis that CMV hyperimmune globulin could have an effect on stopping congenital infections and results of a trial.
The Value of Clinic Champions
Gregory Felzien, MD, AAHIVS, highlights “clinic champions” who help move patient care forward while facing external constraints.
Long-Acting Antiretrovirals and the Cost of HIV Therapies
Carlos del Rio, MD, discusses advances in long-acting antiretrovirals and the costs associated with HIV therapies.
Peer Engagement for Navigating HIV Care
Representatives from the AIDS Care Group discuss the racial disparities that exist in the HIV/AIDS care continuum for women of color, as well as how a peer engagement and retention program can help.
What to Expect in December's News & Breakthroughs Section of Contagion®
In the December issue of Contagion®, Carlos del Rio, MD, Debra Goff, PharmD, and Paul Sax, MD, discuss the benefit of infectious disease clinicians using Twitter.
Why is it Important to Promote U=U?
Timothy Ray Brown, also known as the "Berlin Patient" discusses why it's important to push out the message that U=U.